CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis

CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis

Detalhes bibliográficos
Main Authors:	Lutgens, E, Mulder, WJM, Monaco, C
Outros Autores:	CHECKPOINT ATHERO consortium
Formato:	Journal article
Idioma:	English
Publicado em:	Oxford University Press 2023

Registos relacionados

Risk factors in coronary atherosclerosis athero-inflammation: the meeting point
Por: Altman Raul
Publicado em: (2003-07-01)

Immune checkpoints as therapeutic targets in autoimmunity
Por: Paluch, C, et al.
Publicado em: (2018)

Acute coronary disease Athero-Inflammation: Therapeutic approach
Por: Altman Raul
Publicado em: (2003-06-01)

The ATHERO-AF Study
Por: Michael D. Ezekowitz, MBChB, DPhil, et al.
Publicado em: (2024-08-01)

Immune Checkpoints as Therapeutic Targets in Autoimmunity
Por: Christopher Paluch, et al.
Publicado em: (2018-10-01)

Cell-specific and athero-protective roles for RIPK3 in a murine model of atherosclerosis
Por: Sarah Colijn, et al.
Publicado em: (2020-01-01)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
Por: Pal Maurovich-Horvat, et al.
Publicado em: (2023-07-01)

Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
Por: Esther Lutgens, et al.
Publicado em: (2022-09-01)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
Por: Florian Huemer, et al.
Publicado em: (2021-01-01)

Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
Por: Esther Lutgens, et al.
Publicado em: (2020-05-01)

Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma
Por: Vafa Meftahpour, et al.
Publicado em: (2022-01-01)

Therapeutic Ultrasound-Enhanced Immune Checkpoint Inhibitor Therapy
Por: Jinyun Yuan, et al.
Publicado em: (2021-03-01)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
Por: Naoki Hama, et al.
Publicado em: (2022-01-01)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Por: Akintunde Akinleye, et al.
Publicado em: (2019-09-01)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
Por: Naoki Hama, et al.
Publicado em: (2020-10-01)

From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer
Por: Yibin Zhou, et al.
Publicado em: (2024-02-01)

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Por: Stephanie C. Pitts, et al.
Publicado em: (2024-05-01)

Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine
Por: Pournima Kadam, et al.
Publicado em: (2020-11-01)

Immune checkpoint molecules in prevention and development of asthma
Por: Zahra Kanannejad, et al.
Publicado em: (2023-02-01)

Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
Por: Esther Lutgens, et al.
Publicado em: (2021-06-01)

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
Por: Jared M. Newton, et al.
Publicado em: (2019-08-01)

The Alcohol–High-Density Lipoprotein Athero-Protective Axis
Por: Corina Rosales, et al.
Publicado em: (2020-07-01)

Immune checkpoint analysis in ear cancer
Por: M. Klein, et al.
Publicado em: (2023-11-01)

Biomarkers for immune checkpoint blockers
Por: Kirsty Wienand, et al.
Publicado em: (2018-06-01)

Immune Checkpoints in Viral Infections
Por: Huiming Cai, et al.
Publicado em: (2020-09-01)

Immune checkpoint blockade in HIV
Por: Celine Gubser, et al.
Publicado em: (2022-02-01)

Immune Checkpoint Inhibitors and the Heart
Por: Diana Larisa Mocan-Hognogi, et al.
Publicado em: (2021-09-01)

Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process
Por: E. Anglés-Cano
Publicado em: (1997-11-01)

Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors
Por: Zafer Gurel, et al.
Publicado em: (2024-10-01)

Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
Por: Magalie Dosset, et al.
Publicado em: (2020-07-01)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Por: Mark P. Chao, et al.
Publicado em: (2020-01-01)

Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets
Por: Xueyin Zhou, et al.
Publicado em: (2022-05-01)

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
Por: Margaret A. McBride, et al.
Publicado em: (2021-02-01)

Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Por: Yujia Zhai, et al.
Publicado em: (2021-04-01)

Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Por: Nicholas Gravbrot, et al.
Publicado em: (2019-10-01)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
Por: Alice Mougel, et al.
Publicado em: (2019-03-01)

Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer
Por: Caroline E. Nunes-Xavier
Publicado em: (2024-09-01)

Low HDL-C level is associated with the development of intracranial artery stenosis: analysis from the Chinese IntraCranial AtheroSclerosis (CICAS) study.
Por: Yining Qian, et al.
Publicado em: (2013-01-01)

Editorial: The therapeutic inhibition of macrophage checkpoints
Por: Alexandre P. A. Theocharides, et al.
Publicado em: (2024-04-01)

CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide.
Por: Kuang-Yuh Chyu, et al.
Publicado em: (2012-01-01)